NDA 021248 · Cephalon
Trisenox
Arsenic Trioxide · Injection
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Oct 20, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Sep 25, 2000
Approved uses
2
Original approval plus efficacy supplements
Registered trials
146
15 Phase 3, 9 recruiting
FAERS reports
2,284
2,190 serious, 303 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: DIFFERENTIATION SYNDROME, CARDIAC CONDUCTION ABNORMALITIES AND ENCEPHALOPATHY INCLUDING WERNICKE'S Differentiation Syndrome: Patients with acute promyelocytic leukemia (APL) treated with TRISENOX have experienced differentiation syndrome, which may be life-threatening or fatal. Signs and symptoms may include unexplained fever, dyspnea, hypoxia, acute respiratory distress, pulmonary infiltrates, pleural or pericardial effusions, weight gain, peripheral edema, hypotension, renal insufficiency, hepatopathy, and multi-organ dysfunction, in the presence or absence of leukocytosis. If differentiation syndrome is suspected, immediately initiate high-dose corticosteroids and hemodynamic monitoring until resolution. Temporarily withhold TRISENOX [see Dosage and Administration ( 2.3 ), Warnings and Precautions ( 5.1 )]. Cardiac Conduction Abnormalities: TRISENOX can cause QTc interval...
What it is approved for
From the label in effect Jun 30, 2022.
TRISENOX is an arsenical indicated: In combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. ( 1.1 ) For induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. ( 1.2 ) 1.1 Newly-Diagnosed Low-Risk APL TRISENOX is indicated in combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. 1.2 Relapsed or Refractory APL TRISENOX is indicated for induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.
Mechanism: The mechanism of action of TRISENOX is not completely understood. Arsenic trioxide causes morphological changes and DNA fragmentation characteristic of apoptosis in NB4 human promyelocytic leukemia cells in vitro. Arsenic trioxide also causes damage or degradation of the fusion protein promyelocytic leukemia (PML)-retinoic acid receptor (RAR)-alpha.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 12, 2018 Supplement 15 · Efficacy · priority review OrphanLetterLabel
- Sep 25, 2000 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanReviewLabelLetter
2 products under this application
- TRISENOX · ARSENIC TRIOXIDE 2MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
- TRISENOX · ARSENIC TRIOXIDE 1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Arsenic Trioxide" as an intervention, any sponsor and status, largest first.
- Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesPivotal-lookingCompleted
The University of New South WalesAcademic, hospital or other
NCT00454480 · 2,000 participants (planned) · Start Aug 2006 · Primary completion Aug 2012
Drug: alemtuzumab; arsenic trioxide and 9 more · For: Leukemia; Myelodysplastic Syndromes
Sites: Basingstoke, United Kingdom; Bath, United Kingdom; Birmingham, United Kingdom · 96 sites in all
- Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APLPivotal-lookingStatus unknown
Shanghai Jiao Tong University School of MedicineAcademic, hospital or other
NCT01987297 · 738 participants (planned) · Start Jun 2012 · Primary completion Dec 31, 2020
Drug: ATRA+Arsenic; ATRA+Chemo · For: Acute Promyelocytic Leukemia
Sites: Shanghai, China
- Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic LeukemiaPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00003934 · 420 participants · Start Jun 1999 · Primary completion Nov 2006
Drug: tretinoin; daunorubicin hydrochloride and 4 more · For: Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Promyelocytic Leukemia (M3); Childhood Acute Promyelocytic Leukemia (M3) and 2 more
Sites: Chicago, Illinois; Winston-Salem, North Carolina
- Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic LeukemiaPivotal-lookingStatus unknown
Christian Medical College, Vellore, IndiaAcademic, hospital or other
NCT00517712 · 400 participants (planned) · Start Jun 2004
Drug: Single agent arsenic trioxide · For: Acute Promyelocytic Leukemia
Sites: Bangalore, India; Trivandrum, India; Mumbai, India · 9 sites in all
- Phase III Trial in Acute Promyelocytic Leukemia PatientsPivotal-lookingCompleted
Gruppo Italiano Malattie EMatologiche dell'AdultoAcademic, hospital or other
NCT00482833 · 276 participants · Start Aug 2007 · Primary completion Sep 2012
Drug: arsenic trioxide; idarubicin and 4 more · For: Leukemia
Sites: Innsbruck, Austria; Linz, Austria; Salzburg, Austria · 110 sites in all
- Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular CarcinomaPivotal-lookingStatus unknown
Guangdong Provincial People's HospitalAcademic, hospital or other
NCT01861912 · 258 participants (planned) · Start Jun 2013 · Primary completion Jun 2016
Drug: Arsenic trioxide intravenous infusion; lipiodol and 1 more · For: Carcinoma, Hepatocellular
- Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCCPivotal-lookingStatus unknown
First Hospital of China Medical UniversityAcademic, hospital or other
NCT02018757 · 250 participants (planned) · Start Jan 2014 · Primary completion Dec 2015
Drug: TACE containing As2O3; TACE containing placebo · For: Carcinoma, Hepatocellular
Sites: Guangzhou, China; Nanjing, China; Shenyang, China · 5 sites in all
- Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) PatientsPivotal-lookingStatus unknown
Hunan Provincial People's HospitalAcademic, hospital or other
NCT02956772 · 190 participants (planned) · Start Nov 2016 · Primary completion Nov 2019
Drug: TACE; Arsenic trioxide · For: Primary Hepatocellular Carcinoma
Sites: Guiyang, China; Changsha, China; Hengyang, China · 9 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- electrocardiogram qt prolonged264
- differentiation syndrome227
- off label use176
- pyrexia107
- pneumonia82
- febrile neutropenia80
- alanine aminotransferase increased79
- dyspnoea75
- neutropenia74
- pleural effusion74
- white blood cell count decreased73
- drug ineffective71
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 141 |
| 2005 | 110 |
| 2006 | 71 |
| 2007 | 64 |
| 2008 | 83 |
| 2009 | 153 |
| 2010 | 38 |
| 2011 | 98 |
| 2012 | 85 |
| 2013 | 45 |
| 2014 | 80 |
| 2015 | 50 |
| 2016 | 56 |
| 2017 | 67 |
| 2018 | 180 |
| 2019 | 103 |
| 2020 | 113 |
| 2021 | 88 |
| 2022 | 149 |
| 2023 | 125 |
| 2024 | 147 |
| 2025 | 149 |
| 2026 | 89 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
Lo-Coco F, Avvisati G, Vignetti M, et al. · N Engl J Med 2013 · Clinical Trial, Phase III, Comparative Study
- Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.
Platzbecker U, Adès L, Montesinos P, et al. · J Clin Oncol 2025 · Clinical Trial, Phase III, Multicenter Study
- Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.
Platzbecker U, Avvisati G, Cicconi L, et al. · J Clin Oncol 2017 · Clinical Trial, Phase III, Multicenter Study
- Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial).
Chen L, Zhu HM, Li Y, et al. · Proc Natl Acad Sci U S A 2021 · Pragmatic Clinical Trial, Research Support, Non-U.S. Gov't
- Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 Trial.
Kutny MA, Alonzo TA, Abla O, et al. · JAMA Oncol 2022 · Equivalence Trial, Research Support, N.I.H., Extramural
- Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study.
Zheng H, Jiang H, Hu S, et al. · J Clin Oncol 2021 · Clinical Trial, Multicenter Study
Sponsor: Cephalon
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.